Purpose. The implementation of interventions to mitigate the causes of opioid-induced oversedation and respiratory depression (OSRD) is reported.
P atient harm due to opioid-induced oversedation and respiratory depression (OSRD) is a nationwide problem involving all opioid preparations and delivery routes. Estimates of lifethreatening respiratory depression are imprecise and vary according to the population being studied, route of administration, and patients' risk factors. A frequency of 0.5% is commonly cited, 1 but this apparently low percentage translates into a high burden of serious events, considering the 51 million surgeries performed annually in the United States 2 and the high rate of opioid use during nonsurgical hospitalizations. In one study of 1.14 million admissions, 51% of nonsurgical patients received opioids, with nearly a quarter of those patients receiving more than 100 mg/ day of oral morphine equivalents. 3 Other risk factors, including obesity, advanced age, sleep apnea, and comorbidities, are common among patients in U.S. hospitals, 4 as is the use of nonopioid sedating medications, all of which contribute to OSRD. 5 Opioid safety is further compromised by the variability of dose effect among individuals and the numerous agents and dosage forms, e680 AM J HEALTH-SYST PHARM | VOLUME 73 | 2016 records of each patient receiving naloxone to confirm that the OSRD was likely due to opioids and not from other causes. Criteria for inclusion included an altered level of alertness from baseline as identified and documented in nursing or physician notes, a respiratory rate of <8 breaths/min, recent opioid use with or without other sedating medications, clinical response to naloxone, and the absence of other explanations (e.g., stroke, hypoglycemic coma) that appeared in the medical record. For each adverse opioid event, a primary pharmacist reviewer reconstructed the case and presented it to the review group, which included two physicians, two nurses, and two pharmacists.
In order to understand the underlying causes of OSRD events at our institution, the group analyzed each validated case, focusing on both individual and system or cultural errors. A dynamic system of underlying which often require conversion as outpatients become inpatients.
Problem
OSRD occurred at an unacceptable frequency-more than five times per month-in our hospital. We sought to understand the full range of underlying causes of opioid-induced OSRD and to identify and implement multilevel solutions to reduce the rate of OSRD.
Background
Anne Arundel Medical Center is a 383-bed acute care hospital that serves a region of over 1 million people, with approximately 26,000 admissions and 7,900 inpatient surgeries each year. Inpatient care is predominantly provided by general medical hospitalists on both the medical and surgical floors. The intensive care unit is staffed by fellowship-trained intensivists only, but no trainees contributed to the care of the patients described herein. The hospital uses an electronic medical record (EMR) (Epic Systems, Verona, Wisconsin) for all order writing, documentation, vital sign recordation, and medication flow sheets.
Analysis and resolution
Identification and review of adverse opioid events. Our hospital's institutional review board (IRB) identified this project as a qualityimprovement initiative and thus exempt from IRB review. With naloxone use as an indicator, all cases of potential OSRD in children and adults were identified from a pharmacy database. Naloxone use in the emergency department (ED) was excluded only if the OSRD episode was a result of opioid use before arrival at the ED. If naloxone use was due to an opioid received as therapy in our ED, it was counted among our cases. We also excluded naloxone use when given to hasten arousal from anesthesia in the operating room.
A multidisciplinary team of pharmacists, nurses, and physicians, drawn from existing harm-reduction committees, reviewed the medical
KEY POINTS
• Many patients in acute care hospitals have risk factors for opioid-induced oversedation and respiratory depression (OSRD).
• Underlying causes of OSRD can be classified as knowledge deficits, inadequate sedation monitoring, failure to leverage the electronic medical record (EMR) to guide dosing decisions, and cultural issues related to pain goals and sedation management.
• Solutions that utilize the EMR to create meaningful clinical decision support and lead to cultural changes related to pain goals and communication about sedation level can reduce the frequency of opioidinduced OSRD.
causes was developed as cases were reviewed (Table 1) . Patient risk factors were chosen from eight known patient-level risk factors 5 : age of >60 years, body mass index (BMI) of >30 kg/m 2 , diagnosis of sleep apnea, active cigarette smoker, use of other sedating medications, opioid naive, comorbidities of the lungs, and comorbidities of the kidneys. Since the hospital did not routinely collect data from sleep apnea screening tools, such as the STOP-Bang probability scale, 6 this score was not considered in the risk factor calculation. Diagnosed sleep apnea was included if entered in the "problem list" of the patient.
To further understand the areas of potential knowledge deficits among prescribers, a locally modified opioid knowledge assessment tool 7 was administered to prescribing hospitalists, including physicians and physician assistants. Two additional questions assessing knowledge about crosstolerance when converting between agents and the benefit of monitoring for sedation were added ( Table 2) . These data formed the basis of targeted education and the development of computerized decision support.
A total of 57 episodes of confirmed opioid-induced OSRD events were identified in the preintervention baseline year (March 1, 2013, through March 31, 2014. These 57 patients had a median of five patient risk factors (range, two to six); the most common risk factor was age of >60 years (found in 90% of cases).
Based on this review and case reconstructions, several underlying causes for opioid-induced OSRD were identified at our institution and categorized (Table 1) . Some cases were associated with more than one underlying cause.
Deficits in knowledge about opioid prescribing and safety were common among 24 staff hospitalists surveyed. Table 2 lists the general topics assessed by the opioid knowledge assessment and the hospitalists' scores. Notable knowledge deficits were identified in the areas of definition of opioid toler- e682 AM J HEALTH-SYST PHARM | VOLUME 73 | 2016
ance, dosage adjustment strategies, and the value of sedation levels and respiratory rate when monitoring patients. Prescribers were also unfamiliar with the preferred sedationmonitoring tool. We found that hydromorphone was commonly used in our ED for complaints of pain, six times more commonly than morphine. Some of these patients were admitted and subsequently given hydromorphone administered via patient-controlled analgesia (PCA) infusion pumps.
Interventions implemented. Based on the findings of the case reviews and results of the opioid knowledge assessments, a series of interventions to address noted deficiencies was implemented over the ensuing months, including enhanced monitoring for sedation, improved clinical decision support in the EMR, and various adjustments to dosing for high-risk patients. The solutions used to address these deficiencies are summarized in Table 3 .
Enhanced monitoring for sedation. Our institution lacked a standard approach for opioid sedation monitoring, including an interval of assessments and the steps to follow if patients were found to be oversedated. As noted in Table 2 , there were prescriber knowledge deficits about the relationship between sedation and respiratory depression. To address these deficits, education efforts were prepared for both prescribers and nursing team members. We identified the Pasero Opioid Sedation Scale (POSS) as an evidence-based and easy to apply method of monitoring patients' sedation levels; this scale includes suggested action steps for nursing and medical staff. 8 The tool was piloted on the hospital's joint and spine unitthe clinical unit with the most cases of OSRD at baseline-and then rolled out to all adult units with nonventilated patients. The POSS was incorporated into the EMR to facilitate documentation, assessment, and patient care actions by nursing. The rollout of the POSS was facilitated by mandatory annual POSS education for all nurses via the online education software used at the medical center. All new nurse employees receive classroom education on pain management and POSS administration based on the new policies. The education is reinforced with the inclusion of the POSS in the nursing bedside shift report. Compliance with the POSS was tracked in each individual unit, with random audits of over 30 patients each. The compliance rates for POSS documentation were 88% for first opioid administration and 76% for subsequent doses within a few months of the rollout.
Clinical decision support. The EMR was leveraged to provide prescriber support, including linking a pharmacy and therapeutics committee-approved opioid equivalency table into every order for opioids. The table prominently displayed the recommended advisory that dosage reduction should be considered when switching drugs due to incomplete cross-tolerance and individual patient factors. 9 To facilitate informed prescribing with opioids, an integrated documentation flow sheet was created for all clinicians within the EMR. It gathered together and displayed within a single-screen view any related information needed for safe prescribing and monitoring, such as pain scores, vital signs, sedation score, and analgesic doses given.
In addition, prescribing of preoperative long-acting opioids was removed from most electronic medical order sets. In the few in which it remained, the dose of preoperative extended-release oxycodone was reduced from 20 to 10 mg.
PCA. Beginning in August 2015, the EMR was also used to guide dosing for patients receiving PCA infusions. In the test environment, initial criteria for dose reduction included age of >60 years, BMI of >30 kg/m 2 , creatinine clearance of <30 mL/min, a known diagnosis of emphysema or sleep apnea, or concurrent use of any central nervous system (CNS) depressant (i.e., anxiolytics, hypnotics, or skeletal muscle relaxants); the presence of any of these criteria would have invoked reduced dosing for 90% of all patients using PCA. We therefore modified the criteria by increasing the age to ≥70 years, raising the BMI to ≥37 kg/m 2 , and narrowing the list of potential CNS active drugs to include benzodiazepines only, since this class was most often associated with OSRD at our institution. This form of clinical decision support was built as an order set default to a lower dosing range. The alert for patients meeting any of the criteria would result in lower default demand doses (from 1.5 to 1.0 mg for morphine and from 0.3 to 0.2 mg for hydromorphone) and to a lower default four-hour lockout limit (from 30 to 24 mg for morphine and from 6 to 4.8 mg for hydromorphone). The reduced dose was modifiable by prescribers based on their clinical judgment and patient history. As basal rates of opioids are nearly five times more likely to cause respiratory depression than on-demand dosing, 10 institutional PCA orders continued to avoid a basal rate.
Because hydromorphone was overrepresented in OSRD cases, we took a number of steps to encourage the use of morphine rather than hydromorphone and to make hydromorphone use safer. ED physicians indicated that they preferred hydromorphone 1-or 2-mg doses because the available dose of morphine in the automated drug-dispensing system was too often ineffective at a dose of 4 mg. Thus, a higher dose of morphine (8 mg) was added in addition to the 4-mg dose. We also lowered the default dose of hydromorphone in the pain order set from 1 to 0.5 mg. We implemented a "soft alert" for doses exceeding 1 mg of hydromorphone, which served to reinforce education about proper dosing to ED staff.
Measurable outcomes. The primary endpoint of our analysis was naloxone use for documented cases of opioid-induced OSRD. Figure 1 shows a sustained fourfold reduction in the number of validated naloxone interventions during the study period; these reductions have been sustained for two years. These improvements occurred despite a 41% increase in surgeries with a high risk of OSRD (thoracic, bariatric, and orthopedic), 5 though total hospital patient-days declined by 3.5% over the study period. Overall opioid use decreased just 3% for the hospital.
The interventions to provide safer PCA dosing resulted in lower doses at initiation in 63% of all PCA orders. These EMR-generated clinical decision support recommendations were rarely overridden by medical staff. Over the course of these interventions, there was no change in overall patient satisfaction with regard to pain management, as measured by the Hospital Consumer Assessment of Healthcare Providers and Systems survey, a standard patient satisfaction tool.
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Discussion
The primary goal of this qualityimprovement project was to understand the underlying causes of and intervene to eliminate opioid-induced OSRD at our hospital. Because deaths from opioid-induced OSRD are rare, we relied on the surrogate marker of validated naloxone use as an indicator of clinical OSRD. Naloxone administration is a useful proxy, as naloxone is routinely administered for OSRD and is easily tracked by pharmacy databases. However, naloxone use can be nonspecific; therefore, all instances of its use were reviewed by experienced clinicians to verify that the patient actually had opioid-induced OSRD.
The improvements described in this article have been sustained for two years, and we attribute this success to institutional learning in four important areas: (1) the close relationship between sedation and subsequent respiratory depression with its attendant need for sedation monitoring, (2) enhanced caution about the transfer of sedated patients from the postanesthesia care unit, (3) the avoidance of extended-release opioids in opioidnaive patients, and (4) the reappraisal of pain management goals by reducing the focus on a numeric pain score in isolation from other patient factors. All four concepts are emphasized in e684 AM J HEALTH-SYST PHARM | VOLUME 73 | 2016 professional education, clinical decision support tools, and a culture that has moved toward the discussion of sedation levels concurrently with pain levels. We also sustain success by continuing to review all cases of naloxone use.
The POSS has been shown to generate consistent assessments and had high levels of user satisfaction in several studies. [12] [13] [14] [15] The tool was developed specifically for opioid sedation monitoring and incorporating specific action steps for nurses to follow when a certain sedation level is observed. The POSS also increased the amount of dialogue about sedation during interdisciplinary rounds and was included in shift-to-shift nursing handoffs.
Other institutions have reported on opioid OSRD events. Pawasauskas et al. 4 performed a retrospective casecontrol analysis of patients receiving opioids, regardless of whether they developed respiratory depression. Statistically significant differences between cases and controls were noted for age; current smoking; concurrent sedating medications; and renal, cardiac, and respiratory comorbidities but not opioid-naive status. Patients who developed OSRD had a mean of 5.1 risk factors compared with controls, who had a mean of 3.3 risk factors (p < 0.001). Cases received 13% more morphine equivalents than non-OSRD controls, suggesting that overdosing may have played some role but not likely the principal role. We found a similar number of recognized risk factors in our study of OSRD patients. Many of our opioid-naive patients received extended-release opioids, which may account for the difference between our findings and those of Pawasauskas and colleagues. 4 Meisel et al. 16 reported a similar study focusing on postoperative patients. Some of the interventions they found helpful overlap our own improvements, including efforts to standardize pain assessments and monitoring, lower doses for high-risk patients, and require better handoffs of sedated patients.
This analysis had several limitations. Like many pre-post intervention studies in which solution bundles are implemented simultaneously, we cannot say which solution was most significant in achieving results. In addition, we used one particular EMR to introduce solutions that might not be transferable to other less comprehensive EMRs. The fact that nearly all hospital care, including postsurgical care, is rendered by hospitalists and hospi- Implementation of revised PCA order set talist physician assistants allowed us to concentrate education efforts on a relatively small group of about 45 prescribers and not on a larger cadre of residents or on the entire medical staff of 1000 practitioners. In addition, data collection about patient satisfaction with pain management strategies was not limited to the approximately one half of our patients who received opioids and were thus affected by these changes.
Nevertheless, many of the institutional deficiencies found in this report have been described previously and are common in hospitals. For example, failure to monitor patients adequately was a factor in 29% of adverse opioid outcomes reported to the Joint Commission data base. 5 In addition, a closed claim analysis of 92 postoperative opioid-induced respiratory depression-related lawsuits concluded that 97% were preventable with better monitoring and response. 17 The role of sustained-release opioids used in orthopedic patients deserves special mention. Despite the fact that there are drug label precautions about use of sustained-release opioids in opioid-naive patients, some surgeons incorporated these agents into preoperative order sets in a wellintentioned effort to facilitate early mobilization. But at least one randomized trial found a higher oversedation rate and no better pain control or reduction in total opioid use with preoperative long-acting opioids in joint arthroplasty patients. 18 Indeed, a recent multisociety guideline noted no proven benefit from this practice. 19 We noted that hydromorphone was overrepresented in episodes of OSRD and took the described steps to reduce hydromorphone use. A pattern of care at our hospital was to initiate this drug in the ED. It was thus frequently continued on the inpatient floors as a PCA. Other studies have suggested that currently recommended starting doses of hydromorphone or the recommended conversions are too high. 15, 20, 21 A recent study found that lowering the standard dose of hydromorphone via automatic substitution improved patient safety and did not reduce the adequacy of pain relief. 21 Notably, the improvements described herein were achieved without the use of supplemental oximetry and capnography monitoring which some researchers have advocated. [22] [23] [24] These techniques require both capital outlay and possibly increased labor expenses. In addition, the proliferation of alarms following expanded electronic monitoring has been implicated in patient safety incidents. 25 Recent multisociety professional guidelines do not recommend the use of oximetry or capnography outside of the operating room. 19 
Conclusion
Implementation of solution bundles that utilized an EMR to create meaningful clinical decision support and cultural changes related to pain goals and communication about sedation level at an acute care hospital resulted in a fivefold reduction in OSRD events that has been sustained for two years.
